Cargando…

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks

OBJECTIVE: To characterize the management and outcomes of life-threatening laryngeal attacks of hereditary angioedema (HAE) treated with icatibant in the observational Icatibant Outcome Survey (NCT01034969) registry. METHODS: This retrospective analysis was based on data from patients with HAE type...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longhurst, Hilary J., Aberer, Werner, Bouillet, Laurence, Caballero, Teresa, Maurer, Marcus, Fabien, Vincent, Zanichelli, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892758/ https://www.ncbi.nlm.nih.gov/pubmed/27116379 http://dx.doi.org/10.1097/MEJ.0000000000000292

Ejemplares similares

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
por: Longhurst, H. J., et al.
Publicado: (2017)

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
por: Bygum, Anette, et al.
Publicado: (2019)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries
por: Caballero, T., et al.
Publicado: (2017)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II
por: Floccard, Bernard, et al.
Publicado: (2012)

Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
por: Longhurst, Hilary J., et al.
Publicado: (2018)

Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant
por: Bouillet, Laurence, et al.
Publicado: (2017)

Long‐term safety of icatibant treatment of patients with angioedema in real‐world clinical practice
por: Zanichelli, A., et al.
Publicado: (2017)

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
por: Maurer, Marcus, et al.
Publicado: (2022)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

Hereditary angioedema: epidemiology, management, and role of icatibant
por: Ghazi, Aasia, et al.
Publicado: (2013)

454 Efficacy of Icatibant Versus Fresh Frozen Plasma for Attacks of Hereditary Angioedema: Analysis of Indivudual Symptoms by Attack Site
por: Lara, Alicia, et al.
Publicado: (2012)

Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk
por: Reshef, A, et al.
Publicado: (2015)

Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study
por: Campos, Regis Albuquerque, et al.
Publicado: (2014)

Therapeutic trial in hereditary angioedema type III: Icatibant
por: Garro, Laila Sabino, et al.
Publicado: (2015)

Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
por: Blasco, Antonio J, et al.
Publicado: (2013)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Icatibant in the Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
por: Crooks, Neil H., et al.
Publicado: (2014)

164 Treatment of Acquired Angioedema with the Bradykinin Receptor Antagonist Icatibant
por: Siani, Maria Concetta, et al.
Publicado: (2012)

Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant
por: Ho, Peter, et al.
Publicado: (2014)

Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain
por: Guilarte, Mar, et al.
Publicado: (2021)

A novel therapeutic concept for the treatment of acute angioedema attacks in hereditary angioedema patients: multiple successful treatments even in severe swelling attacks with the bradykinin-B2 receptor antagonist Icatibant
por: Bas, M, et al.
Publicado: (2006)

Case report of treatment with Icatibant for recurrent throat swelling due to hereditary angioedema
por: Chung, Arthur G, et al.
Publicado: (2010)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies
por: Bonner, Nicola, et al.
Publicado: (2015)

Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study()
por: Grumach, Anete S., et al.
Publicado: (2022)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Acquired angioedema
por: Cicardi, Marco, et al.
Publicado: (2010)

Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review
por: Yeung, Erin K., et al.
Publicado: (2018)

Fast 3: a phase III randomized double-blind, placebo-controlled multicenter study of Icatibant for subcutaneous injection in patients with acute Attacks of Hereditary Angioedema (HAE)
por: Ritchie, B
Publicado: (2010)

165 Early Versus Delayed Treatment of Swelling Attacks with Icatibant, a Bradykinin 2 Receptor Antagonist in Patients With Hereditary Angioedema due to C1-INH Deficiency
por: Bork, Konrad, et al.
Publicado: (2012)

Idiopathic Angioedema: Current Challenges
por: Belbézier, Aude, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_620l4gjbeb2n1kpa6ljo5illft